Existing research suggests that less time spent on dialysis before transplant can improve patient outcomes and
survival after transplant.
Not exact matches
When jaundice mounts, and liver failure is likely, a liver
transplant may offer hope, for the five - year
survival rate
after this operation with the use of cyclosporine has been reported to be better than 60 percent.
While some previous studies found that maintenance lenalidomide
after autologous hematopoietic stem cell
transplant improved overall
survival for newly diagnosed multiple myeloma patients, others showed no benefit to this approach.
The study, «Lenalidomide (LEN) maintenance (MNTC)
after high - dose melphalan and autologous stem cell
transplant (ASCT) in multiple myeloma (MM): A meta - analysis (MA) of overall
survival (OS),» is ASCO 2016 abstract no. 8001 and will be discussed during the Hematologic Malignancies — Plasma Cell Dyscrasia oral abstract session Friday, June 3.
Researchers compared 10 - year
survival after being listed for
transplant using two opposing strategies: waiting for a donor heart to which the candidate does not have antibodies or taking the first suitable offer, regardless of potential problems that antibodies may pose.
Steatosis — when the liver becomes infiltrated with fat — occurs frequently
after liver transplantation, but little is known about its actual prevalence in
transplant recipients, which risk factors are involved, or what effects the condition has on patients»
survival.
As we are now able to focus our efforts on improving the overall patient experience and reducing the risk of relapse, the leading cause of death
after transplant, we have greatly improved long - term
survival outcomes for patients who before might not have had another treatment option.»
«Immunotherapy drug nearly eliminates severe acute graft - versus - host disease: Drug used to treat rheumatoid arthritis improves
survival after hematopoietic stem cell
transplant.»
Dr. David Metz, a gastroenterologist at the University of Pennsylvania who conducted a 2005 literature review on liver
transplant for neuroendocrine tumor metastases, said
survival is variable: «Some recur in a year; others, a few years
after surgery.»
«Overall
survival for patients with HIV infection
after transplant is comparable to that seen in people who were not HIV - infected,» said lead author Joseph Alvarnas, MD, associate clinical professor in the department of hematology and director of value - based analytics at the City of Hope National Medical Center in Duarte, CA.
A traditional goal of salvage therapy in the refractory / relapsed population has been to transition patients to
transplant, but in trials of inotuzumab and blinatumomab, there has been no clear impact on
survival after censoring patients at the time of
transplant.
After seeing significantly improved long - term
survival and integration of the
transplanted cells, the next step was to see if the cells actually functioned.
Persistent
survival of the
transplant was not required in order to obtain benefit
after transplantation, as behavioral recovery was as extensive in animals in which
transplanted cells were still present at 5 weeks as in those in which no human cells were detected at this time point.